Fig. 6

Combined application of anti-VEGF and anti-EGFR antibodies attenuates the activation of AKT and ERK, but not STAT3, c-Myc and NF-κB in vivo. a Western blot analysis was performed to determine the activation of AKT, ERK1/2 and STAT3 in different SW620 cells tumors. b Western blot assay of different LoVo cells tumors (one clone, a). c Western blot analysis was performed to determine the activation of c-Myc, NF-κB/p65 and IκBα in different SW620 cells tumors. d Western blot assay of different LoVo cells tumors (one clone, c)